Portal de Periódicos da CAPES

Effects of Intermittent Interleukin‐2 Therapy on Plasma and Tissue Human Immunodeficiency Virus Levels and Quasi‐Species Expression

2000; Oxford University Press; Volume: 182; Issue: 4 Linguagem: Inglês

10.1086/315821

1537-6613

Joseph A. Kovacs, Hiromi Imamichi, Susan Vogel, Julia A. Metcalf, Robin Dewar, Michael Baseler, Randy Stevens, Joseph W. Adelsberger, Laurie Lambert, Richard T. Davey, Robert Walker, Judith Falloon, Michael A. Polis, Henry Masur, H. Clifford Lane,

HIV/AIDS Research and Interventions

To characterize the effects of intermittent interleukin (IL)—2 therapy on human immunodeficiency virus (HIV), 11 patients underwent detailed virological evaluation during a year of IL-2 therapy. Six patients showed a 10.5 log increase in plasma HIV during at least 1 IL-2 cycle, with 2 experiencing an increase in >50% of cycles. Three of the remaining 5 patients had a >0.5 log decrease during at least 1 IL-2 cycle, and the remaining patients exhibited <0.5 log changes. No changes in lymphoid (tonsil) levels of HIV were seen during the year. Quasispecies analysis in a separate cohort demonstrated that the virus induced by IL-2 most commonly resembled pre—IL-2 plasma quasi species. Thus, intermittent IL-2 does not result in sustained increases in either plasma or tissue levels of HIV and does not result in sustained expression of a previously silent quasi species.